Concepedia

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

Alan K. Burnett, Nigel H. Russell, Jonathan Kell, Michael Dennis, Donald Milligan, Stefania Paolini, John Yin, Dominic Culligan, Peter Johnston, John Murphy,

Journal of Clinical Oncology · 2010 · 148 citations · 13 references

DOIFull text

Open access

Abstract

Clofarabine is active and generally well tolerated in this patient group. It is worthy of further evaluation in comparative trials and might be of particular use in patients with adverse cytogenetics.

References

13

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.6K citations

, , +18

Age and acute myeloid leukemia

Frederick R. Appelbaum, Holly Gundacker, David R. Head et al. · Blood · 2006 · 1.3K citations · Full text

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

David Grimwade · Blood · 2001 · 915 citations · Full text

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Alan K. Burnett, Donald Milligan, Archie Prentice et al. · Cancer · 2007 · 613 citations · Full text

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes et al. · Cancer · 2006 · 606 citations · Full text